US 11,051,496 B2
Urokinase-type plasminogen activator transgenic mouse
Michinori Kohara, Tokyo (JP); Koichi Jishage, Gotemba (JP); Yosuke Kawase, Gotemba (JP); Chise Mukaidani, Higashihiroshima (JP); Hiroki Oshita, Higashihiroshima (JP); and Satoko Hamamura, Higashihiroshima (JP)
Assigned to TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, Tokyo (JP); CHUGAI SEIYAKU KABUSHIKI KAISHA, Tokyo (JP); and PHOENIXBIO CO., LTD., Higashihiroshima (JP)
Filed by TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, Tokyo (JP); CHUGAI SEIYAKU KABUSHIKI KAISHA, Tokyo (JP); and PHOENIXBIO CO., LTD., Higashihiroshima (JP)
Filed on Mar. 23, 2018, as Appl. No. 15/934,520.
Application 15/934,520 is a continuation of application No. 14/397,091, granted, now 9,955,675, previously published as PCT/JP2013/062806, filed on Apr. 25, 2013.
Claims priority of application No. 2012-102814 (JP), filed on Apr. 27, 2012.
Prior Publication US 2019/0335724 A1, Nov. 7, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A01K 67/027 (2006.01); C12N 9/72 (2006.01); C12N 15/85 (2006.01); C12N 15/877 (2010.01); G01N 33/50 (2006.01)
CPC A01K 67/0275 (2013.01) [A01K 67/0271 (2013.01); C12N 9/6462 (2013.01); C12N 15/8509 (2013.01); C12N 15/8775 (2013.01); G01N 33/5067 (2013.01); G01N 33/5088 (2013.01); A01K 2207/12 (2013.01); A01K 2207/15 (2013.01); A01K 2217/052 (2013.01); A01K 2217/15 (2013.01); A01K 2217/206 (2013.01); A01K 2227/105 (2013.01); A01K 2267/035 (2013.01); A01K 2267/0337 (2013.01); C12N 2015/8581 (2013.01); Y10T 436/146666 (2015.01)] 11 Claims
 
1. A chimeric mouse having a chimeric liver that contains transplanted human hepatocytes, wherein:
the chimeric mouse is an immunodeficient mouse having a uPA gene in a heterozygous form;
the mouse does not exhibit rejection against hepatocytes from a different animal origin;
the human hepatocytes were transplanted in an amount between 1 and 2,000,000 cells;
the blood human albumin concentration is 1 mg/mL or higher;
the uPA gene is in the form of cDNA encoding uPA and linked to a liver specific promoter;
and the blood human albumin concentration increases for at least 10 weeks after transplantation of the human hepatocytes,
wherein the chimeric mouse has a replacement rate of human hepatocytes of 60% or more.